Amgen Canada Inc., a subsidiary of Amgen Inc.(NASDAQ:AMGN), has launched product sales in Canada ofNeupogen granulocyte colony stimulating factor. Neupogenstimulates white blood cells in cancer patients undergoingchemotherapy. The drug, which was approved in the UnitedStates in February 1991, received Canadian governmentapproval last month. Amgen had $232 million in worldwideNeupogen sales last year.
(c) 1997 American Health Consultants. All rights reserved.